Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

References

• Cornuz J. Smoking cessation interventions in clinical practice. Eur J Vasc Endovasc Surg 2007;34:397-404
   PubMed Web of Science ®Google Scholar
• U.S. Public Health Service. Fiore MC, Jaén CR, Baker TB, et al. (Guideline panel). Treating tobacco use and dependence: 2008 update. Clinical practice guideline. U.S. Department of Health and Human Services. Public Health Service, May 2008. Available at ww.surgeongeneral.gov/tobacco/default.htm [Last accessed: 25 June 2008]
   Google Scholar
• World Health Organization. Comparative Quantification of Health Risks. Global and Regional Burden of Disease Attribution to Selected Major Risk Factors. World Health Organization, 2005. Available at: http://www.who.int/publications/cra/en/index.html. [Last accessed: 25 June 2008]
   Google Scholar
• Duodecim. Smoking, nicotine dependence and nicotine withdrawal. Current Care Guideline. Working group set up by the Finnish Medical Society Duodecim and the Finnish Association for General Practice, 2007. Available at: www.duodecim.fi/kh [Last accessed: 25 June 2008]
   Google Scholar
• European Commission. Attitudes of Europeans towards tobacco. Special Eurobarometer 239/Waves 64.1-64.3 -- TNS Opinion & Social. European Commission, 2006
   Google Scholar
• Vollset SE, Tverdal A, Gjessing HK. Smoking and deaths between 40 and 70 years of age in women and men. Ann Intern Med 2006;144:381-9
   PubMed Web of Science ®Google Scholar
• World Health Organization. Why is tobacco a public health priority? Available at: www.who.int/tobacco/health_priority/en/print.html [Last accessed 25 June 2008]
   Google Scholar
• The European Tobacco Control Report 2007. World Health Organization, Regional Office for Europe, Copenhagen, 2007. Available at: www.euro.who.int/document/e89842.pdf [Last accessed: 25 June 2008]
   Google Scholar
• Peto R, Lopez AD, Boreham J, et al. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21
   PubMed Web of Science ®Google Scholar
• Mitrouska I, Bouloukaki I, Siafakas NM. Pharmacological approaches to smoking control. Pulm Pharmacol Ther 2007;20:220-32
   PubMed Web of Science ®Google Scholar
• Janson C, Kunzli N, de Marco R, et al. Changes in active and passive smoking in the European Community Respiratory Health Survey. Eur Respir J 2006;27:517-24
   PubMed Web of Science ®Google Scholar
• Helakorpi S, Patja K, Prättälä R, et al. Health behaviour and health among Finnish adult population, Spring 2006. Helsinki, Finland. National Public Health Institute (KTL), 2007
   Google Scholar
• World Bank. Curbing the epidemic. Governments and the economics of tobacco control. Development in Practice. A World Bank Publication, 1999
   Google Scholar
• Godfrey C, Fowler G. Pharmacoeconomic considerations in the management of smoking cessation. Drugs 2002;62:63-70
   PubMed Web of Science ®Google Scholar
• Parrott S, Godfrey C. Economics of smoking cessation. BMJ 2004;328:947-9
   PubMed Web of Science ®Google Scholar
• Barendregt JJ, Bonneux L, van der Maas PJ. The healthcare costs of smoking. N Engl J Med 1997;337:1052-7
   PubMed Web of Science ®Google Scholar
• Rasmussen SR, Prescott E, Sorensen TIA, et al. The total lifetime health cost savings of smoking cessation to society. Eur J Public Health 2005;15:601-6
   PubMed Web of Science ®Google Scholar
• Vitikainen K, Pekurinen M, Kiiskinen U. Economic impact of smoking cessation. Suom Lääkäril [J Finn Med Ass] 2006;61:2985-9
   Google Scholar
• West R. The clinical significance of ‘small’ effects on smoking cessation treatments. Addiction 2007;102:506-9
   PubMed Web of Science ®Google Scholar
• Pekurinen M. Valuing the cost of smoking. In: Assessment Methods, Risk Perception and Policy Options. Studies in Risk and Uncertainty. Boston: Kluwer Academic Publishers, 1999
   Google Scholar
• Cornuz J, Pinget C, Gilbert A, et al. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol 2003;59:201-6
   PubMed Web of Science ®Google Scholar
• Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No: CD000031. doi: 10.1002/14651858.CD000031.pub3
   Google Scholar
• Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No: CD000146. doi: 10.1002/14651858.CD000146.pub3
   Google Scholar
• Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002;6:1246
   Google Scholar
• Woolacott N, Jones L, Forbes C, et al. A rapid and systematic review of the clinical and cost-effectiveness of bupropion SR and nicotine replacement therapy (NRT) for smoking cessation. NHS R&D HTA Programme. University of York, February 2002
   Google Scholar
• Lightwood J. The economics of smoking and cardiovascular disease. Prog Cardiovasc Dis 2003;46:39-78
   PubMed Web of Science ®Google Scholar
• Feenstra TL, Hamberg-vab Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face smoking cessation intervention: a dynamic modelling study. Value Health 2005;8:178-90
   PubMed Web of Science ®Google Scholar
• Hall SM, Lightwood JM, Humfleet GL, et al. Cost effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. J Behav Health Serv Res 2005;32:381-92
   PubMed Web of Science ®Google Scholar
• Bolin K, Lindgren B, Willers S. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden. Chest 2006;129:651-60
   PubMed Web of Science ®Google Scholar
• Olsen KR, Bilde L, Juhl HH, et al. Cost-effectiveness of the Danish smoking cessation interventions. Subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ 2006;7:255-64
   PubMedGoogle Scholar
• Franco OH, der Kinderen AJ, De Laet C, et al. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care 2007;23:71-9
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008;24:51-61
   PubMed Web of Science ®Google Scholar
• Royal Collage of Physicians. Harm reduction in nicotine addiction. Helping people who can’t quit. A report by the Tobacco Advisory Group of the Royal Collage of Physicians. October, 2007. Available at: http://www.rcplondon.ac.uk/pubs/contents/4fc74817-64c5-4105-951e-38239b09c5db.pdf [Last accessed: 25 June 2008]
   Google Scholar
• EMEA. European Public Assessment Report for Authorized Medicinal Products for Human Use. European Medicines Agency (EMEA). Available at: www.emea.europa.eu/humandocs/Humans/EPAR/champix/champix.htm [Last accessed 25 June 2008]
   Google Scholar
• Varenicline. Summary of product characteristics. 2008. Available at: http://www.pfizer.com/files/products/uspi_chantix.pdf [Last accessed: 25 June 2008]
   Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56 63. Erratum in: JAMA 2006;296:1355
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55
   PubMed Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8
   PubMed Web of Science ®Google Scholar
• Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006;6:300
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No: CD006103. doi: 10.1002/14651858.CD006103.pub2
   Google Scholar
• O’Regan CP, Baker C, Marchant N. The cost-effectiveness of the novel prescription therapy varenicline in Scotland. Meeting of the Society for Research on Nicotine and Tobacco, 2006. Available at: www.srnt.org/meeting/2007/pdf/onsite/2007RapidsBook.pdf [Last accessed 25 June 2008]
   Google Scholar
• Bolin K, Mörk A-C, Willers S, Lindgren B. Varenicline as compared to bupropion in smoking-cessation therapy - cost-utility results for Sweden 2003. Respir Med 2008;102:699-710
   PubMed Web of Science ®Google Scholar
• Hind D, Tappenden P, Peters J, et al. Varenicline for smoking cessation. A single technology appraisal. National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Guidance 123, 2007. Available at: www.nice.org.uk/TA123 [Last accessed June, 25 2008]
   Google Scholar
• Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008;26:497-511
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Welsing P, Rutten-van Mölken MPMH. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in Netherlands. Curr Med Res Opin 2008;24:51-61
   PubMed Web of Science ®Google Scholar
• Igarashi A, Takuma H, Fukuda T, et al. Cost-utility analysis of varenicline, an oral smoking cessation drug, in Japan. Pharmacoeconomics 2009; 27:247-61
   PubMed Web of Science ®Google Scholar
• Keiding H. Cost-effectiveness of varenicline for smoking cessation. Expert Rev Pharmacoecon Outcomes Res 2009;9:215-221
   PubMedGoogle Scholar
• Faulkner MA. Smoking cessation: an economic analysis and review of varenicline. Clincoecon Outcomes Res 2009;1:25-34
   PubMedGoogle Scholar
• Orme ME, Hogue SL, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001;10:55-61
   PubMed Web of Science ®Google Scholar
• Aromaa A, Koskinen S. Health and functional capacity in Finland. Baseline results of the Health 2000 examination survey. Publications of the National Public Health Institute B12/2004. Helsinki, Finland. KTL - National Public Health Institute, 2004. Available at: www.ktl.fi/terveys2000 [Last accessed 25 June 2008]
   Google Scholar
• Ministry of Social Affairs and Health. Asthma Programme in Finland 1994-2004. Working Group Memorandums 1998:21. Helsinki, Finland: Ministry of Social Affairs and Health, 1998. [in Finnish]
   Google Scholar
• Klaukka T, Hirvonen A, Peura S, et al. Treatment situation of asthma in 2001. Key results of the Asthma Barometer. Suomen Lääkärilehti [J Finn Med Ass] 2002;57:292-4. [in Finnish]
   Google Scholar
• Aalto A-M, Klaukka T, Rissanen P, et al. Asthma in the Finnish population of working age. A 1996 survey on health status, use of health care services and need for rehabilitation among persons with asthma. Studies in Social Security and Health 43. Helsinki, Finland: The Social Insurance Institute, 1999
   Google Scholar
• Kinnunen T, Säynäjäkangas O, Keistinen T. The COPD-induced hospitalization burden from first admission to death. Respir Med 2007;101:294-9
   PubMed Web of Science ®Google Scholar
• Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal poly-posis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-22
   PubMed Web of Science ®Google Scholar
• Statistics Finland. Population structure 2006. Helsinki, Finland, 2007. Available at: http://tilastokeskus.fi/til/vaerak/index_en.html [Last accessed: accessed 25 June 2008]
   Google Scholar
• Foulds J, Burke M, Steinberg M, et al. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004;9:39-53
   PubMedGoogle Scholar
• Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38
   PubMed Web of Science ®Google Scholar
• Hujanen T. Healthcare unit costs in Finland in year 2001. Helsinki, Finland: National Research and Development Centre for Welfare and Health (STAKES), 200
   Google Scholar
• Statistics Finland. Available at: http://statfin.stat.fi/StatWeb [Last accessed: February 8, 2007]
   Google Scholar
• Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000;284:706-12
   PubMed Web of Science ®Google Scholar
• Cassino C, Ito K, Bader I, et al. Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City. Am J Respir Crit Care Med 1999;159:1773-9
   PubMed Web of Science ®Google Scholar
• Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicot Tob Res 2002;4:95-100
   PubMedGoogle Scholar
• Wetter DW, Cofta-Gunn L, Fouladi RT, et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004;39:1156-63
   PubMed Web of Science ®Google Scholar
• Decree issued by the Ministry of Social Affairs and Health on the application for a reasonable wholesale price and for the reimbursement status of a medical products and on the documentation to be attached to the application (1111/2005). Annex: Guidelines for preparation of a pharmacoeconomic report
   Google Scholar
• Etter J, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006;15:280-5
   PubMed Web of Science ®Google Scholar
• Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106-8
   PubMed Web of Science ®Google Scholar
• Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004;13:405-15
   PubMed Web of Science ®Google Scholar
• Raftery J. NICE: faster access to modern treatment? Analysis of guidance on health technologies. BMJ 2001;323:1300-3
   PubMed Web of Science ®Google Scholar
• Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ 2004;329:224-7
   PubMed Web of Science ®Google Scholar
• Hawthorne G, Richardson J, Day NA. Comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med 2001;33:358-70
   PubMed Web of Science ®Google Scholar
• Saarni SI, Härkänen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006;15:1403-14
   PubMed Web of Science ®Google Scholar
• Wasley MA, McNagny SE, Phillips VL, et al. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997;26:264-70
   PubMed Web of Science ®Google Scholar
• Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999;354:210-15
   PubMed Web of Science ®Google Scholar
• Javitz HS, Swan GE, Zbikowski SM, et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care 2004;10:217-26
   PubMed Web of Science ®Google Scholar
• Puska P, Korhonen HJ, Uutela A, et al. Anti-smoking policy in Finland. Smokefree Europe. Helsinki. Finnish Centre for Health Promotion, and Ministry of Social Affairs and Health, 1997
   Google Scholar
• World Health Organization. Preventing chronic diseases. A vital investment. World Health Organization, 2005. Available at: www.who.int/chp/chronic_disease_report/full_report.pdf [Last accessed: 25 June 2008]
   Google Scholar
• Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis?. Health Econ 2004;13:417-27
   PubMed Web of Science ®Google Scholar
• Cost-effectiveness of interventions to reduce tobacco smoking in the Netherlands. An application of the RIVM Chronic Disease Model. RIVM, Bilthoven, 2006. Available at: www.rivm.nl/bibliotheek/rapporten/260601003.pdf [Last accessed 25 June 2008]
   Google Scholar